Armata Pharmaceuticals, INC 10-Q quarterly reports

Armata Pharmaceuticals, Inc. reported its second quarter 2026 financial results, highlighting progress in its phage therapy development programs while acknowledging substantial doubt regarding its ability to continue as a going concern.

Armata Pharmaceuticals reported a significant net loss of $115.3 million in Q1 2026, raising substantial doubt about its ability to continue as a going concern despite positive clinical trial advancements and a new $25 million loan.

Armata Pharmaceuticals announced positive Phase 2a results for its lead bacteriophage candidate AP-SA02, but faces significant financial challenges with a going concern warning.

Armata Pharmaceuticals reports increased net losses and a going concern warning despite positive clinical trial results for its bacteriophage therapies.

Armata Pharmaceuticals announces its Q1 2025 financial results, highlighting ongoing clinical trials and a new $4.65 million funding boost for its AP-SA02 bacteremia program.

Armata Pharmaceuticals' Q3 2024 report shows a net loss of $5.481 million, but also highlights progress in clinical trials and a significant increase in grant revenue.

Armata Pharmaceuticals reports a net loss of $16 million for the first half of 2024, while highlighting progress in clinical trials and securing additional funding.

Armata Pharmaceuticals reported a net loss of $25 million for the first quarter of 2024, while securing a $35 million loan to support ongoing operations and clinical trials.